ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base

PROTOKINETIX INC. (PKTX: OTCBB)
VANCOUVER, BRITISH COLUMBIA, OCTOBER 14, 2008

ProtoKinetix (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)), announced today that it has partnered with OTC Financial Network (OTCFN), a division of National Financial Communications Corp. (NFC), to direct a comprehensive shareholder awareness campaign.

'ProtoKinetix' AAGP(TM) platform technology is ideal for a number of applications in the skin care/cosmetics, cellular therapy, blood preservation and pharmaceutical industries,' said Geoffrey Eiten, president of NFC. 'Last month, ProtoKinetix entered into its first licensing agreement to provide AAGP(TM) as the primary active ingredient in an anti-inflammatory cream for the sports injury market. This contract is one of several in the pipeline that position ProtoKinetix on a path to commercial success. We look forward to introducing the Company and its world-class management team to the financial community.'

'We've selected to partner with OTCFN to increase our market awareness and widen our shareholder base,' said Ross L. Senior, President and CEO of ProtoKinetix Inc. 'We are excited to be working with a financial communications firm that has a well respected track record. We believe we can effectively enhance shareholder value by partnering with companies that offer the technical, marketing and distribution expertise to bring AAGP(TM) applications to market.'

About OTC Financial Network

Since 1992, OTC Financial Network (OTCFN) has carved its niche as the nation's leading small/micro-cap investor relations and financial communications firm. OTCFN is a division of National Financial Communications Corp. (http://www.nationalfc.com) based in Needham, MA. For information, visit http://www.otcfn.com.

OTC Financial Network serves as special advisor to ProtoKinetix Inc. and has received fees for services, including two hundred and fifty-thousand shares of restricted stock, in addition to an option to purchase two-hundred fifty-thousand shares at an exercise price of twenty cents per share, for the creation and implementation of an awareness program. This is not an offer to buy or sell securities. Information or opinions in this release are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. A full disclaimer can be found online by visiting http://www.otcfn.com/pktx/disclaimer.html.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP™ products.

For more detailed information, please visit our website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Mr. Ross L. Senior, President and CEO

ProtoKinetix Inc.
Investor Contact
Blair Henderson, 604-687-9887